Eyas Raddad, BPharm, M.B.A., Ph.D.
Associate Vice President, Portfolio Strategy and Novel Therapeutic Platforms Diabetes Obesity and Complications, Lilly Research Laboratories
Decision-making is fundamental to human life. It is what defines our agency, shapes our future, and allows us to accomplish great things as individuals, organizations, societies, and the human race. Developing decision-making skills early on would make individuals healthier, more accomplished and happier; families more prosperous with healthier relationships; organizations more successful and in tune with their missions; and societies more cohesive and more successfully responsive to their citizens’ needs.
Eyas is a seasoned drug discovery and development researcher, strategist, and innovator. Since he joined Eli Lilly and Company in 2001, he applied sophisticated data analytics and strategic frameworks to improve decision-making in drug discovery and development process, and led a group of scientist in his technical area of Parmacokinetics/Pharmacodynamics (PK/PD). He later moved to Chorus, the industry-renowned innovative early development engine, where he established the PK/PD function, and helped advance tens of novel drugs to a decisive proof-of-concept stage, setting a record that is the envy of the industry. He continues to pursue efforts that help increase the productivity of the drug discovery and development innovation cycle. Over his career, he implemented Decision Analytic techniques in drug development applications. In 2017, Eyas established and led the Research Decision Analytics function in Lilly Research Laboratories, with a mission that includes portfolio management, decision consulting, and Decision Education. More recently, he has been serving as COO of multiple early development programs at Eli Lilly, as well as portfolio management role in Diabetes Research. He currently serves as chief strategist and operation leader in Diabetes, Obesity and Complication therapeutic area at Lilly.
A native of Jordan, Eyas holds a B.S. in Pharmacy (University of Jordan; 1997), and a Ph.D. in Pharmaceutics (University of Georgia; 2001). Eyas also completed an M.B.A. from MIT-Sloan School of Management in 2013.
